KADCYLA (ado-trastuzumab emtansine) is used for the treatment of patients with HER2-positive breast cancer.

KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:  Received prior therapy for metastatic disease, or  Developed disease recurrence during or within six months of completing adjuvant therapy

KADCYLA (ado-trastuzumab emtansine) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KADCYLA (ado-trastuzumab emtansine) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ALUNBRIG (brigatinib) tablets cost price in India.

The order for KADCYLA (ado-trastuzumab emtansine) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death.

KADCYLA™ (ado-trastuzumab emtansine) for injection, for intravenous use. Initial U.S. Approval: 2013

Generic Name: brigatinib

Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.

KADCYLA (ado-trastuzumab emtansine) for injection

KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use is available.

Get In Touch

KADCYLA (ado-trastuzumab emtansine) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KADCYLA (ado-trastuzumab emtansine) on prescription and Import License in Patient's Name only.

For overseas patients, KADCYLA (ado-trastuzumab emtansine) can be made available in Send your enquiry to find KADCYLA (ado-trastuzumab emtansine) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for KADCYLA (ado-trastuzumab emtansine).

For KADCYLA (ado-trastuzumab emtansine) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Genentech’s Kadcyla Wins Second FDA Approval for HER2-Positive Breast Cancer For More Details

Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer For More Details

Channel Partner In India

Delhi Office

60/4, T&T House. Yusuf Sarai,
New Delhi:110016

Bangalore Office

#308, Raheja Chambers, 12,
Museum Road, Bangalore 560 001

Kolkata Office

1/A R.G Kar Road, Shayambazar,
Kolkata 700004

Lucknow Office

203-A, 2nd Floor, Tower -11, Felix
Square, IBB-2, Sushant Golf city, Lucknow 226030